Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Observe Medical ASA - Exercise of subscription rights by primary insider

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 27 November 2023 regarding the allocation of subscription rights (the "Subscription Rights") in the rights issue ("Rights Issue") to primary insiders and close associates. Per Arne Nygård, CFO in the Company, has exercised 450,000 Subscription Rights, entitling Per Arne Nygård to be allocated 450,000 offer shares in the Rights Issue at a price per offer share of NOK 0.26, subject to the Rights Issue being completed. For more information see the attached mandatory notification of trade.

Bulletin from Dustin’s Annual General Meeting 2022/23

Dustin Group AB held its Annual General Meeting (AGM) today. The AGM resolved in accordance with all proposals by the Board and the Nomination Committee.The AGM re-elected Stina Andersson, Mia Brunell Livfors, Gunnel Duveblad, Thomas Ekman, Johan Fant, Tomas Franzén and Morten Strand as members of the Board. The AGM further elected Thomas Ekman as new Chair of the Board. The AGM re-elected the registered accounting firm Ernst & Young as auditor for the period until the end of the next AGM. Åsa Lundvall will continue as auditor-in-charge. The AGM approved the annual report for 2022/23 and

Unlocking the power of digital dentistry at the University of Helsinki

In the autumn of 2021, 50 dentistry students embarked on a learning journey within brand-new facilities for dental education at the University of Helsinki. Planmeca delivered simulation equipment for the skills laboratory, in which the students get their first touch to the craftsmanship of dentistry. While Planmeca solutions have facilitated the incorporation of the latest digital technologies into the dentistry curriculum, they have also enabled new approaches to teaching. Two years ago, the dentistry programme at the University of Helsinki found a new home in the recently

Embark on a One Hour Clash for Galactic Dominance in Stellaris Nexus, Now Available in Early Access

Players can now play the fast-paced 4X turn-based strategy game, solo or with up to five friendsStockholm, December 12 - Today, Paradox Interactive and Whatboy Games released Stellaris Nexus into early access on Steam . This immersive sci-fi 4X experience offers players the opportunity to dive into single or multiplayer gameplay and complete matches from start to finish in about one hour. For those who have pre-purchased the game, Stellaris Nexus early access is now up and running, priced at 14.99€ / 12.99£ / 14.99$. Discover

Railway Metrics and Dynamics enters into an agreement with Strainlabs

Smart screws from Strainlabs that detects when the temperature starts to get too high – for example in wheel axles and bearings. They will be a strong complement to Railway Metrics and Dynamics system platform, which uses several different types of sensors to predict faults in trains or tracks. The two companies have entered into a cooperation agreement that makes Railway Metrics and Dynamics' predictions even more reliable.The two Swedish companies Railway Metrics and Dynamics  and Strainlabs  have entered into a cooperation agreement

AMSC ASA: Buyback of own shares and share sale arrangement as part of incentive scheme for employees

On 25 April 2023, the Annual General Meeting of American Shipping Company ASA (“AMSC” or the “Company”) granted the Board of Directors of AMSC an authorization to purchase treasury shares in connection with the Company’s incentive scheme for employees. In accordance with this authorization, the Company will today place an order with an investment broker for purchase of 150,000 treasury shares, with execution from 13 December and onwards. 100,000 shares will be sold to Pål Magnussen, CEO of AMSC, and 50,000 shares will be sold to MB Capital AS, a company controlled by Morten Bakke, CFO of

Fitch affirms Akelius BBB rating but changes outlook to negative

On December 12, Fitch Ratings revised the outlook on Akelius’ credit rating to negative from stable. Akelius’ issuer credit rating has been affirmed at BBB and the senior unsecured rating is affirmed BBB+. The negative outlook reflects the recently announced extra dividend on class A ordinary shares. CEO, Ralf Spann - Akelius continues to be in a very strong financial position, following the guarantee from the owner.  Berlin, 2023-12-12 Ralf SpannCEO+49 173 643 65 90ralf.spann@akelius.de This information is information that Akelius Residential Property AB (publ)

OBSERVE MEDICAL ASA – The Company has received subscriptions for offer shares raising gross proceeds in the rights issue of more than NOK 18,000,000.20 in cash

Oslo, 12 December 2023: Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company (the "Offer Shares"), each with a nominal value of NOK 0.26, at a subscription price of NOK 0.26 per Offer Share (the "Rights Issue"). As previously announced, completion of the Rights Issue is subject to (i) the Company raising gross proceeds in the Rights Issue of minimum NOK 18,000,000.20 in cash and (ii) each of the lenders ("Lenders") (listed in

Avida Finans AB (publ) publishes bond prospectus and applies for admission to trading of bonds on Nasdaq Stockholm

Avida Finans AB (publ) (the "Company") issued on 27 October 2023 subordinated tier 2 bonds in an amount of SEK 250,000,000. The bonds carry a floating interest rate of STIBOR 3m + 9.25 per cent. per annum and mature on 27 January 2034. The Company will apply for admission to trading of the bonds on the Corporate Bond list at Nasdaq Stockholm. The bonds will be admitted to trading at Nasdaq Stockholm as soon as possible. In connection with this, the Company has prepared a prospectus. The prospectus has been approved by, and registered with, the Swedish Financial Supervisory Authority

Changes in Formpipe's organization.

Formpipe is taking several steps to further strengthen its market position. From January 1, 2024 the business areas for the Swedish and Danish public sectors will be merged into one. Thomas à Porta is appointed Executive Vice President, Head of the new Business Area Public. Michael Rogers is appointed Executive Vice President, Head of the Private business area."I intend to lead Formpipe into a new phase of growth. I see great advantages in one organization for our business that target the public sector. The business logic is the same across the national borders. The merger creates clarity

Stora Enso commits to net-zero carbon emissions

STORA ENSO OYJ INVESTOR NEWS 12 December 2023 at 17:00 EETStora Enso commits to reach net-zero carbon emissions by 2040 by becoming a signatory of The Climate Pledge.   Committing to net-zero emissions by signing The Climate Pledge is a logical step for Stora Enso in its long-term ambition to become net carbon positive, and to offer 100% regenerative products and solutions by 2050. Stora Enso remains committed to deliver on its existing 2030 target to reduce absolute Scope 1, 2 and 3 emissions by 50% from the 2019 baseline. This target is aligned with the 1.5-degree scenario and is

100 percent Frem becomes SPACEMANN

ASSMANN takes over leading English manufacturer of room-in-room systemsASSMANN Büromöbel GmbH & Co. KG has completed its takeover of the British Frem Group Screens Limited. The Melle-based family business acquired the remaining 26 percent of shares in one of England’s leading manufacturers of room-in-room systems at the beginning of December. Now renamed SPACEMANN, the company will operate as an independent development and production facility with a clear differentiation to the sales subsidiary ASSMANN Office Furniture Ltd. All of the approximately 40 employees have kept their jobs. “Not

Neonode Launches Sharpened Strategy with Full Focus on Its Licensing Business

STOCKHOLM, SWEDEN, December 12, 2023 — Neonode Inc. (NASDAQ: NEON) today announces a new, sharpened strategy with full focus on its licensing business. Consequently, Neonode will phase out its Touch Sensor Module (“TSM”) product business through licensing of the TSM technology to strategic partners or outsourcing.Neonode has been successful in licensing technology historically and the management team sees the largest potential for future growth and profitability in this area.  The focus will be on licensing of the advanced MultiSensing® platform for driver and in-cabin monitoring and the

Report from the extraordinary general meeting of Cereno Scientific AB (publ)

Today, December 12, 2023, Cereno Scientific AB (publ) held an extraordinary general meeting at MAQS Advokatbyrå's premises at Östra Hamngatan 24 in Gothenburg, Sweden. Chairman of the general meeting was attorney Eric Ehrencrona from MAQS Advokatbyrå.The following main resolutions were resolved at the general meeting: Resolution on adjustment of the terms and conditions for the warrants of series 2023/2026:1 and 2023/2026:4, respectively, and the agreements regarding the respective incentive program The general meeting resolved, in accordance with the board of director’s proposal, to

Fredrik Emilson new CEO of Enviro

Scandinavian Enviro Systems (publ) ("Enviro" or the "Company") has hired Fredrik Emilson, former CEO of Höganäs AB, as the company's new Chief Executive Officer. Emilson takes office in February 2024 at the same time as current CEO Thomas Sörensson moves to a role as senior advisor. Fredrik Emilson. Fredrik Emilson comes most recently from Höganäs AB, where he worked since 2010 and from 2017 as CEO. During his time at Höganäs AB, Fredrik also held the role of European manager followed by the role of responsible for Asia. Höganäs is the world leader in metal powder solutions

John Mattson publishes the preliminary outcome of the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER COUNTRY OR JURISDICTION TO WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE THE PREPARATION OR REGISTRATION OF ADDITIONAL DOCUMENTATION OR REQUIRE ANY OTHER ACTION TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS OF SWEDISH LAW. THIS PRESS RELEASE IS NOT A PROSPECTUS BUT AN ANNOUNCEMENT IN CONNECTION WITH THE PLANNED NEW ISSUE OF

Atrium Ljungberg changes its dividend policy and strengthens its execution power of the project portfolio

Atrium Ljungberg will conduct its business with low financial risk-taking in order to enable the implementation of profitable and value-creating urban development projects. In the light of increased investment pace in urban development projects, the Board of Directors believes that a lower dividend payout ratio will be appropriate and has therefore decided on a new dividend policy.The company has a project portfolio corresponding to an investment volume of approximately SEK 40 billion in already owned land or obtained land allocations. The investments, with implementation over the next 10–

Stayble Therapeutics Phase IIb data support effectiveness in treating herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") today presents further analyses from the Phase IIb study on degenerative disc disease (DDD) and its impact on the Company's other project on lumbar disc herniation (LDH). In patients who received the higher dose of STA363, a statistically significant difference was observed in disc intensity and disc height, which are clear signs of reduced disc volume. These effects should lead to a decrease in the volume of the herniation and, thus, pain reduction in patients with herniated discs.In the ongoing analyses of results from the DDD study, a

The district court approves YA Holding’s subsidiary YrkesAkademin AB’s request for an extension of the restructuring

As announced through a press release on 1 December 2023, YA Holding AB’s (publ) (“YA Holding”) wholly owned subsidiary YrkesAkademin AB submitted a request to the district court regarding an extension of the ongoing company restructuring that same date. YA Holding now announces that Falu District Court today approved YrkesAkademin AB’s request for an extension of the company reconstruction with an additional three (3) months up to and including 4 March 2024. For more information on the background to the company restructuring, press here 

The sale of YIT’s renewable energy business to Eolus completed

YIT Corporation Investor News 12 December 2023 at 3:15 p.m.The sale of YIT's renewable energy business, YIT Energy Oy, to Eolus Vind Ab has been completed. YIT announced the sale on 5 December 2023. The transaction consists of a fixed and a variable purchase price. The fixed purchase price is EUR 25 million, which will be paid in three instalments. The first instalment of EUR 10 million has been paid at closing and EUR 15 million will be paid in two instalments during 2024 and 2025. The variable purchase price is defined based on project sales and completed projects and it amounts to

OBSERVE MEDICAL ASA – Major shareholders have converted their loans in the rights issue and/or entered into amendment agreements

Oslo, 12 December 2023: Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company (the "Offer Shares"), each with a nominal value of NOK 0.26, at a subscription price of NOK 0.26 per Offer Share (the "Rights Issue"). As previously announced, completion of the Rights Issue is subject to (i) the Company raising gross proceeds in the Rights Issue of minimum NOK 18,000,000.20 in cash and (ii) each of the lenders ("Lenders") (listed in

Form 8.3 - Hotel Chocolat Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):    The naming of nominee or vehicle companies isinsufficient.  For a trust, the trustee(s),settlor and beneficiaries must be named.(c) Name of offeror/offeree in relation to whose Hotel

Report from Extraordinary General Meeting of Embellence Group AB (publ)

Embellence Group AB (publ) held on Friday 8 December 2023 an extraordinary general meeting at MAQS Advokatbyrå’s premises at Stureplan 19 in Stockholm, Sweden. Fredrik Brusberg, associate at MAQS Advokatbyrå, was elected as chairman of the general meeting.The following main resolutions were resolved upon at the general meeting: Election of board of directors and the chairman of the board of directorsThe general meeting resolved, in accordance with a shareholder group’s proposal, to re-elect the existing board members Karin Dennford, Anneli Kansbod, Henrik Nyqvist, and Christina Ståhl

Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy

Stockholm, Sweden – December 12, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the development of innovative antifungal therapies, is pleased to announce that the Company’s partner, Alkem Laboratories Limited (“Alkem”), has submitted a Clinical Trial Application to the Central Drugs Standard Control Organization (CDSCO) in India. The application pertains to the initiation of the first patient study for BSG005, Biosergen’s leading antifungal drug candidate, a clinical trial designed to address unmet medical needs in invasive fungal

There are no items matching the current filter
There are no more items matching the current filter
Back to top